The effect of sorafenib and intermittent hepatic arterial infusion chemotherapy using cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombus-a pilot study

Japanese Journal of Cancer and Chemotherapy

Volumn 37, Issue 12, 2010, Pages 2679-2682

  Ishizaki, Morihiko ^a   Kaibori, Masaki ^a   Matsui, Kosuke ^a   Yanagimoto, Yasuaki ^a   Nakatake, Richi ^a   Kwon, A Hon ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Cisplatin; HAIC; Sorafenib; Unresectable advanced HCC

Indexed keywords

AMYLASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CISPLATIN; SORAFENIB;

ABDOMINAL PAIN; ADVANCED CANCER; AGED; AMYLASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEPATIC ARTERIAL INFUSION CHEMOTHERAPY; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERTENSION; INOPERABLE CANCER; INTRAARTERIAL DRUG ADMINISTRATION; LIVER CELL CARCINOMA; MALE; NEUTROPENIA; PILOT STUDY; PORTAL VEIN; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR THROMBUS;

EID: 84866623720     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Llovet JM, Bustamante J, Castelles A, et al Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 29(1):62-67.1999. (Pubitemid 29023987)
2. Yoshikawa M. Ono N, Yodono H, et al Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular caccinoma. Hepatol Res 38 (5): 474-483.2008. (Pubitemid 351593948)
3. Cooley ME. Davis L. Abrahm J. et al Cisplatin: A clinical review. Part II-Nursing assessment and management of side effects of cisplatin. Cancer Nurs 17(4): 283-293,1994. (Pubitemid 24255418)
4. Yamashita T, Arai K, Sunagozaka H, et ai. Randomised, phase II study comparing interferon combined 5-fluoro-uracil plus cisplatin hepatic arterial infusion with interferon combimed 5-fluorouracil hepatic arterial infusion in patients with advanced hepatocellular carcinoma. J Clin Oncol 27:15s. 2009.
5. Jeung HC, Rha SY. Noh SH, et al: A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer. Cancer Chemother Pharmacol 59 (3): 313-320. 2007. (Pubitemid 46025518)
6. Shinoyama S, Imamura K, Hiki N, et al. Performance of outpatient regimen of S-l in combination with fractional cisplatin for advanced or recurrent gastric cancers: a phase I study. Int J Clin Oncol 10(4):251-255.2005. (Pubitemid 41242179)
7. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (4): 378-390.2008.
8. Chen FS. Cui YZ. Luo RC, et al Coadministration of sorafenib and cisplatin inhibits proliferation of hepatocellular carcinoma HepG2 cells in vitro. Nan Fang Yi Ke Da Xue Xue Bao 28(9): 1684-1687. 2008.